However, in the last years, several studies have established positive associations between enhanced circulating visfatin/Nampt levels and atherogenic inflammatory diseases, therefore supporting a role for visfatin as a potential biomarker of cardiovascular complications associated to metabolic disorders. This evidence concerns the gene NAMPT and Other metabolic disease.